In a nutshell The study aimed to investigate if home-based physical activity was effective in improving the symptoms of patients with breast cancer who were receiving primary treatment. This study concluded that home-based physical activity is effective in improving some outcomes for these...
Read MoreIn a nutshell This phase 2 study will investigate the effectiveness of experimental medication tucatinib and trastuzumab (Herceptin) to treat brain metastases in HER2-positive breast cancer (BC). The main outcome will be overall survival (OS). This trial is recruiting in Alabama and Texas, the US. The details...
Read More
In a nutshell This study is examining the effectiveness of biological drug sacituzumab govitecan (IMMU-132) compared to standard treatments for patients with hormone receptor-positive metastatic breast cancer. The main outcomes that will be measured are cancer responsiveness to the drug and survival of patients without the cancer growing. This trial...
Read More
In a nutshell This study wanted to find out what the long-term outcomes were for women with ductal carcinoma in situ (DCIS) who had breast-conserving therapy. The study found that after 10 years, the risk of recurrence of cancer in the same breast was very low. Some background There are a number of treatment options for DCIS. Some women opt...
Read MoreIn a nutshell This study aimed to investigate the combination of letrozole and taselisib as a neoadjuvant treatment (before surgery) in patients with hormone receptor-positive, HER2-negative, early stage breast cancer. This study concluded that this treatment...
Read More
In a nutshell This phase 1/2 trial will investigate the safety of OBT076 in patients with advanced breast cancer. The main outcomes will be the frequency of side effects and response to treatment. This trial is recruiting at Columbia University Medical Center, NY, US. The details Breast cancer (BC) is a highly treatable...
Read More
In a nutshell This trial is examining the most beneficial dose of an experimental AE37 vaccine when used with biological therapy pembrolizumab (Keytruda). The main outcomes to be measured are the maximum safest dose of AE37 and objective response rate. This study is recruiting in Illinois and West Virginia, US. The details Triple-negative...
Read MoreIn a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors. They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...
Read More
In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with solid tumors such as triple-negative breast cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...
Read MoreIn a nutshell This study aimed to investigate the effectiveness and safety of talazoparib as a neoadjuvant agent (treatment before surgery) in patients with BRCA mutation and operable breast cancer. This study concluded that this treatment was a safe and effective in these patients. Some...
Read MoreIn a nutshell This trial will evaluate a molecular test, EndoPredict®, in the treatment of breast cancer. The main outcome will be the adherence rate to EndoPredict® results. This trial is recruiting in South Carolina, USA. It is sponsored by Myriad Genetic Laboratories. The details Adjuvant chemotherapy (ACT) is...
Read More
In a nutshell This study aimed to investigate the impact of early side effects requiring ado-trastuzumab emtansine dose interruptions or reductions on outcomes for patients with HER2+ advanced metastatic breast cancer. This study concluded that these side effects do not impact the outcomes for these patients. Some background...
Read More
